1383056-73-2 Usage
General Description
2-(tert-butoxycarbonylamino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid is a chemical compound that belongs to the pyrimidine family and contains a carboxylic acid group. It is commonly used in medicinal chemistry as a building block for the synthesis of various pharmaceuticals. The presence of the carbonyl group and the amino group in the compound makes it suitable for use in the formation of peptide linkages and protein synthesis. This chemical has potential applications in the development of new drugs and therapeutics due to its unique structure and reactivity. It is also used in biochemical research and as a reagent in organic synthesis.
Check Digit Verification of cas no
The CAS Registry Mumber 1383056-73-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,8,3,0,5 and 6 respectively; the second part has 2 digits, 7 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1383056-73:
(9*1)+(8*3)+(7*8)+(6*3)+(5*0)+(4*5)+(3*6)+(2*7)+(1*3)=162
162 % 10 = 2
So 1383056-73-2 is a valid CAS Registry Number.
1383056-73-2Relevant articles and documents
Substituted heteroaryl compounds and compositions and uses thereof
-
Paragraph 0463-0464; 0481-0482, (2017/12/02)
The invention discloses a substituted ceteroary compound as well as a composition and an application thereof. The compound is a compound shown in a formula (I) or a stereisomer, a tautomer, a nitric oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The invention further discloses a pharmaceutical composition including the compound. The compound and the pharmaceutical composition are capable of adjusting the activity of the AK kinase and can be used for preventing, processing, treating and relieving the JAK-mediated disease or disorder.
5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
-
Paragraph 0478, (2015/12/05)
Compounds of Formula (00A) and methods of use as Janus kinase inhibitors are described herein.
